JP2025073123A5 - - Google Patents
Info
- Publication number
- JP2025073123A5 JP2025073123A5 JP2025016352A JP2025016352A JP2025073123A5 JP 2025073123 A5 JP2025073123 A5 JP 2025073123A5 JP 2025016352 A JP2025016352 A JP 2025016352A JP 2025016352 A JP2025016352 A JP 2025016352A JP 2025073123 A5 JP2025073123 A5 JP 2025073123A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- nucleotide
- pharmaceutical composition
- sequence
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962817904P | 2019-03-13 | 2019-03-13 | |
| US62/817,904 | 2019-03-13 | ||
| US201962856432P | 2019-06-03 | 2019-06-03 | |
| US62/856,432 | 2019-06-03 | ||
| PCT/US2020/022738 WO2020186207A2 (en) | 2019-03-13 | 2020-03-13 | Non-viral dna vectors and uses thereof for expressing fviii therapeutics |
| JP2021554696A JP7795357B2 (ja) | 2019-03-13 | 2020-03-13 | Ｆｖｉｉｉ治療薬を発現するための非ウイルス性ｄｎａベクターおよびその使用 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021554696A Division JP7795357B2 (ja) | 2019-03-13 | 2020-03-13 | Ｆｖｉｉｉ治療薬を発現するための非ウイルス性ｄｎａベクターおよびその使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025073123A JP2025073123A (ja) | 2025-05-12 |
| JP2025073123A5 true JP2025073123A5 (https=) | 2025-08-06 |
Family
ID=72426821
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021554696A Active JP7795357B2 (ja) | 2019-03-13 | 2020-03-13 | Ｆｖｉｉｉ治療薬を発現するための非ウイルス性ｄｎａベクターおよびその使用 |
| JP2025016352A Pending JP2025073123A (ja) | 2019-03-13 | 2025-02-03 | Ｆｖｉｉｉ治療薬を発現するための非ウイルス性ｄｎａベクターおよびその使用 |
| JP2025172911A Withdrawn JP2026002894A (ja) | 2019-03-13 | 2025-10-14 | Ｆｖｉｉｉ治療薬を発現するための非ウイルス性ｄｎａベクターおよびその使用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021554696A Active JP7795357B2 (ja) | 2019-03-13 | 2020-03-13 | Ｆｖｉｉｉ治療薬を発現するための非ウイルス性ｄｎａベクターおよびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025172911A Withdrawn JP2026002894A (ja) | 2019-03-13 | 2025-10-14 | Ｆｖｉｉｉ治療薬を発現するための非ウイルス性ｄｎａベクターおよびその使用 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US12338275B2 (https=) |
| EP (1) | EP3938523A4 (https=) |
| JP (3) | JP7795357B2 (https=) |
| KR (1) | KR20210151785A (https=) |
| CN (1) | CN113874513A (https=) |
| AU (1) | AU2020234713A1 (https=) |
| BR (1) | BR112021017853A2 (https=) |
| CA (1) | CA3133255A1 (https=) |
| IL (1) | IL286284A (https=) |
| MA (1) | MA55313A (https=) |
| MX (1) | MX2021011039A (https=) |
| SG (1) | SG11202109850SA (https=) |
| WO (1) | WO2020186207A2 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202545984A (zh) | 2017-08-09 | 2025-12-01 | 美商生物化學醫療公司 | 核酸分子及其用途 |
| WO2020033863A1 (en) | 2018-08-09 | 2020-02-13 | Bioverativ Therapeutics Inc. | Nucleic acid molecules and uses thereof for non-viral gene therapy |
| CN116234917A (zh) | 2020-07-27 | 2023-06-06 | 安杰瑞姆生物科学公司 | Dna分子组合物及其制备方法和使用方法 |
| US20220356490A1 (en) * | 2020-08-23 | 2022-11-10 | Bioverativ Therapeutics Inc. | Baculovirus expression system |
| US20250027107A1 (en) | 2021-10-18 | 2025-01-23 | Flagship Pioneering Innovations Vii, Llc | Dna compositions and related methods |
| US20240335564A1 (en) * | 2021-11-02 | 2024-10-10 | Gritgen Therapeutics Limited | Isolated nucleic acid molecule and use thereof |
| JP2023089774A (ja) * | 2021-12-16 | 2023-06-28 | 株式会社三洋物産 | 遊技機 |
| JP2025504404A (ja) * | 2022-01-14 | 2025-02-12 | アンジャリウム バイオサイエンシズ エージー | Ｖｉｉｉ因子をコードするｄｎａ分子の組成物、それを作製する方法、及びその使用方法 |
| WO2025110984A1 (en) * | 2023-11-21 | 2025-05-30 | Hydrogene Therapeutics, Inc. | Compositions and methods for treating wilson's disease |
| KR20260011950A (ko) | 2024-07-17 | 2026-01-26 | 이민형 | 수질 시료 채취 드론 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009067548A1 (en) * | 2007-11-19 | 2009-05-28 | The Regents Of The University Of California | Novel assay for inhibitors of egfr |
| JP2012525134A (ja) * | 2009-04-30 | 2012-10-22 | サイトス バイオテクノロジー アーゲー | インフルエンザ赤血球凝集素の組成物とその使用 |
| EP2500434A1 (en) | 2011-03-12 | 2012-09-19 | Association Institut de Myologie | Capsid-free AAV vectors, compositions, and methods for vector production and gene delivery |
| WO2013093760A2 (en) * | 2011-12-19 | 2013-06-27 | Grifols, S.A. | Compositions, methods, and kits for preparing sialylated recombinant proteins |
| AU2013243948A1 (en) * | 2012-04-02 | 2014-10-30 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins associated with human disease |
| SI3889173T1 (sl) | 2013-02-15 | 2023-11-30 | Bioverativ Therapeutics Inc. | Optimiran gen dejavnika VIII |
| RS61039B1 (sr) * | 2013-09-12 | 2020-12-31 | Biomarin Pharm Inc | Aav vektori koji sadrže gen koji kodira faktor viii |
| GB2526339A (en) | 2014-05-21 | 2015-11-25 | Imp Innovations Ltd | Lentiviral vectors |
| KR20180034467A (ko) * | 2015-08-03 | 2018-04-04 | 마이오도파 리미티드 | L-dopa의 전신 합성 및 조절 |
| RU2742352C2 (ru) | 2015-09-24 | 2021-02-05 | Байомарин Фармасьютикал Инк. | Векторы фактора fviii на основе аденоассоциированных вирусов, соответствующие вирусные частицы и содержащие их терапевтические композиции |
| CA3002524A1 (en) * | 2015-10-28 | 2017-05-04 | Sangamo Therapeutics, Inc. | Liver-specific constructs, factor viii expression cassettes and methods of use thereof |
| PE20231949A1 (es) * | 2015-10-30 | 2023-12-05 | Spark Therapeutics Inc | VARIANTES DEL FACTOR VIII REDUCIDO CON CpG, COMPOSICIONES Y METODOS Y USOS PARA EL TRATAMIENTO DE TRASTORNOS DE LA HEMOSTASIA |
| WO2017152149A1 (en) * | 2016-03-03 | 2017-09-08 | University Of Massachusetts | Closed-ended linear duplex dna for non-viral gene transfer |
| KR102450833B1 (ko) * | 2016-04-15 | 2022-10-05 | 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 | 혈우병 a 치료용 유전자 요법 |
| KR102219859B1 (ko) * | 2016-06-24 | 2021-02-25 | 재단법인 목암생명과학연구소 | 재조합 단쇄 fviii 및 그 화학 접합물 |
| AU2018312565A1 (en) * | 2017-08-01 | 2020-02-27 | Spark Therapeutics, Inc. | Factor VIII (FVIII) gene therapy methods |
| TW202545984A (zh) * | 2017-08-09 | 2025-12-01 | 美商生物化學醫療公司 | 核酸分子及其用途 |
-
2020
- 2020-03-13 WO PCT/US2020/022738 patent/WO2020186207A2/en not_active Ceased
- 2020-03-13 CN CN202080036209.7A patent/CN113874513A/zh active Pending
- 2020-03-13 SG SG11202109850S patent/SG11202109850SA/en unknown
- 2020-03-13 US US17/437,123 patent/US12338275B2/en active Active
- 2020-03-13 KR KR1020217029545A patent/KR20210151785A/ko active Pending
- 2020-03-13 EP EP20769344.1A patent/EP3938523A4/en active Pending
- 2020-03-13 CA CA3133255A patent/CA3133255A1/en active Pending
- 2020-03-13 MA MA055313A patent/MA55313A/fr unknown
- 2020-03-13 MX MX2021011039A patent/MX2021011039A/es unknown
- 2020-03-13 AU AU2020234713A patent/AU2020234713A1/en active Pending
- 2020-03-13 BR BR112021017853A patent/BR112021017853A2/pt unknown
- 2020-03-13 JP JP2021554696A patent/JP7795357B2/ja active Active
-
2021
- 2021-09-12 IL IL286284A patent/IL286284A/en unknown
-
2025
- 2025-02-03 JP JP2025016352A patent/JP2025073123A/ja active Pending
- 2025-05-21 US US19/214,171 patent/US20250282848A1/en active Pending
- 2025-10-14 JP JP2025172911A patent/JP2026002894A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025073123A5 (https=) | ||
| Stillman et al. | Identification of the gene and mRNA for the adenovirus terminal protein precursor | |
| CN112040988A (zh) | 修饰的aav衣壳多肽用于治疗肌肉疾病 | |
| TW202128193A (zh) | 一種基於ｌｅａｐｅｒ技術治療ｍｐｓ ｉｈ的方法和組合物 | |
| JP2003527856A5 (https=) | ||
| JP2019017390A (ja) | 特定遺伝子の発現を抑制するための方法および薬剤 | |
| BR112023015177A2 (pt) | Ácido nucleico compreendendo smn1 e mir-23a para tratamento da atrofia muscular espinhal, cassete de expressão, vetor de expressão, vírus recombinante, composição farmacêutica, uso e método relacionados | |
| CN112004559A (zh) | 用于在线粒体内表达蛋白质的核酸、包封有所述核酸的脂质膜结构体和它们的应用 | |
| Li et al. | RNA nanotechnology to build a dodecahedral genome of single-stranded RNA virus | |
| JP2003519241A (ja) | 二層型鉱物粒子に取り込まれた核酸を含む組成物 | |
| JPWO2023039424A5 (https=) | ||
| CN114438106B (zh) | Rv2779c基因及其表达产物作为抗结核分枝杆菌靶点的应用 | |
| CN105754999B (zh) | 一种抑制hsa-miR-221-3p的寡核苷酸序列、重组腺病毒及其制备方法和应用 | |
| Bolwig et al. | Different binding site requirements for binding and activation for the bipartite enhancer factor EF-1A | |
| CN107073078B (zh) | 利用肝细胞生长因子和基质细胞衍生因子1α的用于预防或治疗外周动脉疾病的组合物 | |
| CN116004725A (zh) | 间充质干细胞在疼痛相关疾病中的应用 | |
| JPWO2022204093A5 (https=) | ||
| JPWO2023025193A5 (https=) | ||
| US20250121096A1 (en) | Engineered liver-specific enhancers and their applications | |
| JPWO2023018858A5 (https=) | ||
| CN120361033A (zh) | miRNA-149-5p及其激动剂在制备脓毒症肺损伤治疗药物中的应用 | |
| JPWO2022236147A5 (https=) | ||
| CN101857877A (zh) | 含tfpi基因与gfp基因双顺反子的逆转录病毒真核表达载体及构建方法及应用 | |
| Heinlein | Thomas Hohn (1938-2023) | |
| CN118546234A (zh) | 基因工程改造获得的分泌能力和凝血活性增强的人类八因子 |